Drug Profile
Cellspan oesophageal implant - Harvard Apparatus Regenerative Technology
Alternative Names: Cellspan-Paediatric-Oesophageal-Implant; Cellspan™ Esophageal Implant-Adult; Oesophageal stem cell implant - Harvard Apparatus Regenerative TechnologyLatest Information Update: 23 Aug 2023
Price :
$50
*
At a glance
- Originator Biostage
- Developer Harvard Apparatus Regenerative Technology; Mayo Clinic
- Class Mesenchymal stem cell therapies
- Mechanism of Action Tissue replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Oesophageal disorders
Most Recent Events
- 21 Aug 2023 Cellspan oesophageal implant - Harvard Apparatus Regenerative Technology receives Orphan Drug status for Oesophageal atresia in European Union
- 20 Jul 2023 Biostage is now called Harvard Apparatus Regenerative Technology
- 13 Jul 2023 Phase-I clinical trials in Oesophageal-disorders in USA (Implant) (NCT05877300)